Fair value · Health Catalyst, Inc. (HCAT) · updated 2026-10-29 · from 10-K FY2025
Health Catalyst trades at $1.82. That price implies a 10.6% free-cash-flow yield.
Cboe · delayed 15 min · as of 20:05 ET
Are those assumptions reasonable? Use HCAT’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.
What the price implies
- FCF yield
- 10.6%
free cash flow ÷ enterprise value (9.4× EV/FCF)
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings. This price: Cboe · delayed 15 min · as of 20:05 ET.
Inputs come from the FY2025 10-K filed (accession 0001636422-26-000035); set your own on the sliders below. Research, not investment advice.
The filing behind these numbers
Health Catalyst, Inc.- Revenue
- $311.1M
- Diluted EPS
- $-2.55
- Free cash flow
- $-237000
- operating cash flow − capital expenditure
- Diluted shares
- 69.9M
- weighted average
10-K FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-12 · accession 0001636422-26-000035
Trailing-twelve-month EPS also uses the quarterly 10-Qs through Q2 FY2026 (filed 2026-08-06).
Open this filing on sec.govNeed HCAT data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.